<DOC>
	<DOCNO>NCT02573714</DOCNO>
	<brief_summary>The purpose study determine use ketamine , sniff nose , safe effective way help reduce pain pediatric sickle cell patient pain crisis resource-limited setting .</brief_summary>
	<brief_title>Sub-dissociative Intranasal Ketamine Pediatric Sickle Cell Pain Crises</brief_title>
	<detailed_description>This randomize , placebo-controlled , drug trial use sub-dissociative intranasal ketamine adjunct standard pharmacotherapy management pediatric sickle cell disease vasoocclusive pain crisis resource-poor setting . Pediatric patient enrol teach referral hospital West Africa . Patients randomly assign treatment arm - standard therapy plus sub-dissociative intranasal ketamine ( 1 mg/kg ) give time zero ) control arm - standard therapy plus intranasal normal saline ( volume-matched treatment arm ) , patient evaluate standard interval assess pain score vital sign ( 0 minute , 30 minute , 60 minute , 120 minute ) . Pain assess use Faces Pain Scale - Revised ( FPS-R ) . Patients also observe potential side effect adverse event . All patient contact 2-3 week post intranasal medication administration over-the-phone follow-up use portion PedsQL-SCD questionnaire , ass basic quality life relate pain management treatment .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Sickle cell disease ( SCD ) Vasoocclusive pain crisis Requiring analgesia Anatomic variation nose preclude intranasal medication administration Ketamine allergy Nonverbal Obtunded Pregnant Other acute SCD complication : Acute chest syndrome Sepsis Stroke Splenic sequestration Pulmonary embolism Acute osteomyelitis</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Ketamine</keyword>
	<keyword>Intranasal</keyword>
	<keyword>Pain crisis</keyword>
	<keyword>Vasoocclusive Pain</keyword>
	<keyword>Sickle cell disease</keyword>
</DOC>